remain bullish option health rais target
multipl roll ebitda rcm/bad debt/fcf
gener remain key sector tailwind plenti see upward bia
synergi estim view compani well posit on-going
shift toward valu addit continu view bio strateg posit
scale independ provid key differenti competit
advantag view recent renewed/expand multi-year contract
aet encourag data point reiter buy
infus hard argu remain bullish home infus
industri continu see meaning strateg benefit includ cost
advantag vs set patient prefer treatment home
potenti safeti advantag strong underli growth trend addit
shift toward valu base care on-going payor focu site
care redirect grow acut benefit home-bas care
becom increasingli obviou view overal industri well posit
scale independ home infus provid highli fragment
industri think option boast enviabl strateg posit
aid broad payor access in-network top payer
portfolio limit distribut drug also view recent renew multi-
year contract unit healthcar buy aetna
buy key detail encourag data point given
payor intern capabl briovarx/dplo cvs/aet coram
expand contract inclus payer prefer network
minim pen stroke risk govern pay mix limit payer
concentr payor make revenu broad
portfolio therapi balanc mix acut chronic revenu
split like compani diversif think lower risk
detail recent upbeat payer news roughli month post merger
close integration/synergi captur well underway compani see
progress across sever key area synergi realiz track within
procur buy best contract benefit increment scale
 expect network save footprint optim
 expect continu high convict
upward bia target synergi also bullish increment headway
payor front recent multi-year contract renewals/expans
tr target
share count pro forma reflect bioscrip/
aetna contract bring legaci option bio
pharmaci one agreement leverag nation footprint provid bio access
payer limit prefer network offer potenti leverag ldd portfolio
compani also recent announc select highmark prefer provid
factor product treatment/manag hemophilia patient start januari
view announc anoth attract posit highlight compani differenti
capabl think like creat halo effect time
opportun one key benefit merger simplifi capit structur improv
liquid net-debt ebitda progress revenu cycl management/bad debt
free cash flow gener remain key work done area execut
key also see opportun given legaci bio challeng around rcm/bad debt combin
compani abil better leverag technolog infrastructure/improv collect trend time
estim assum on-going de-lever tie ebitda growth free cash flow generation/debt pay
view manag commentari recent confer regard progress/
increas veloc cash collect addit reason optim
opportun abound rais rais price target vs prior
 ebitda vs prior ebitda reflect on-going bullish around
underli core trend inher industri tailwind superb strateg posit work remain
rcm/cash flow improv execut critic compani uniqu posit
scale independ nation provid home infus servic see signific opportun
forese futur market shift toward valu base care view core
oper platform meaning inher valu compani also file earli januari
announc revers stock split view posit split expect effect
compani expect begin trade nasdaq global select exchang connect
revers split plan chang ticker reiter buy rate
page
revenu
revenu
revenu
revenu
equiti earn jv
revenu
page
nation provid infus servic compani locat cover
popul includ full servic pharmaci ambulatori infus suit bio partner
patient physician hospit healthcar payor pharmaceut manufactur provid clinic
manag solut deliveri cost-effect access prescript medic larg
home recent merger bioscrip/opt ad scale expand payor access enhanc
therapi offer provid attract synergi mprove capit structur
continu recogn inher valu core busi compani servic carri
benefit patient prefer treat home payor lower-cost set recent
merger provid strateg benefit oper synergi provid attract capit
structur free cash flow gener remain key given heavi debt load view risk/reward
favor rate share buy
valuat risk
price target base stock trade adjust ebitda modest discount
pure play home base care provid view appropri given debt load risk
rate price target includ integr challeng failur gener free cash flow pay
debt failur execut strateg initi
compani mention note
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
